An Evolving Landscape: New Therapies for Metastatic Colorectal Cancer

This publication has 69 references indexed in Scilit:

• Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials
  Annals of Oncology, 2023
• Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study
  eClinicalMedicine, 2023
• P-71 KRYSTAL-10: A randomized phase 3 study of adagrasib (MRTX849) in combination with cetuximab vs chemotherapy in patients with previously treated advanced colorectal cancer with KRASG12C mutation
  Annals of Oncology, 2021
• Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET
  Journal of Biological Chemistry, 2021
• KRAS: From undruggable to a druggable Cancer Target
  Cancer Treatment Reviews, 2020
• Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer
  JAMA, 2018
• Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses
  JAMA Oncology, 2018
• Differential Effector Engagement by Oncogenic KRAS
  Cell Reports, 2018
• Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer
  Cancer Cell, 2018
• Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
  The Lancet, 2013